Last reviewed · How we verify
Vitex Agnus Castus Extract
Vitex Agnus Castus Extract, marketed by Nazgul Omarbayeva, is a plant-based therapeutic currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that could be leveraged for market dominance. The primary risk lies in the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market penetration.
At a glance
| Generic name | Vitex Agnus Castus Extract |
|---|---|
| Also known as | Mastodynone |
| Sponsor | Nazgul Omarbayeva |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea (PHASE3)
- An Investigation of Premama Balance and Its Effects on Hormonal Imbalances (NA)
- Possibilities of Phytomedicine in Monotherapy of Benign Breast Diseases (PHASE4)
- A Study to Explore the Effect of Vitex Negundo and Zingiber Officinale on Non-specific Chronic Low Back Pain Due to Sedentary Lifestyle (NA)
- Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52 (PHASE4)
- Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS (PHASE3)
- Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitex Agnus Castus Extract CI brief — competitive landscape report
- Vitex Agnus Castus Extract updates RSS · CI watch RSS
- Nazgul Omarbayeva portfolio CI